Administration of an antibody against ENPP1 also rescues post-infarct metabolic defects in a humanized mouse model of myocardial infarction [47]. For patients with ENPP1 deficiency, ERT is already under investigation in a phase 1/2 study (NCT04686175, ClinicalTrials.gov). Here, ELF3 is linked to myocardial infarction.